Investors looking to estimate a fair value for Hinduja Leyland Finance (HLF) shares in the unlisted market can effectively use NDL Ventures’ current market price as a benchmark. HLF’s valuation, post its merger with NDL Ventures, hinges critically on NDL’s listed stock price, making it imperative for investors in the secondary market of HLF to track NDL’s price movements for their valuation decisions.
HLF and NDL Ventures are undergoing a merger where the conversion ratio is set such that 1 HLF share converts into 2.5 NDL Ventures shares. NDL Ventures’ current share price is approximately ₹98.1 in the listed market. This conversion ratio means the fair value of HLF can be estimated by multiplying NDL Ventures’ share price by 2.5.
Based on the latest NDL Ventures price, HLF’s fair value in the unlisted market stands near ₹245.25. However, HLF is reportedly trading at around ₹265 in unlisted markets, indicating a premium of about 7.5% over its merger-based fair value. This premium reflects market inefficiencies, demand-supply dynamics in the unlisted segment, and investor sentiment.
HLF’s book value per share is ₹160, and the fair value based on NDL prices results in a price-to-book ratio (P/B) of approximately 1.53x, which is reasonable given the financial health and sector context of HLF.
Several factors cause HLF’s price to command a premium over the exact merger conversion math:
Although the ticker HLF is used here for Hinduja Leyland Finance unlisted shares, it is essential to clarify for investors that Herbalife Ltd. (HLF) on NYSE is a publicly listed global nutrition company with notable competitors in the consumer products space.
| Aspect | Herbalife Ltd. (HLF) | Prestige Consumer Healthcare (PBH) |
| Revenue | $4.99 Billion | $1.14 Billion |
| Price/Earnings Ratio (P/E) | 2.63 | 14.62 |
| Net Margin | 6.59% | 19.02% |
| Return on Equity (ROE) | -27.36% | 12.69% |
| Stock Volatility (Beta) | Moderate | Low |
| Analyst Rating Score | 2.60 (Moderate Buy) | 2.43 (Moderate Buy) |
Herbalife trades at a lower P/E ratio, indicating affordability, but it shows weaker profitability and ROE compared to Prestige Consumer Healthcare, which implies a more stable profit model and better operational efficiency. Investors should weigh such fundamentals carefully alongside valuation multiples when assessing these listed competitors.
Key Drivers Affecting HLF’s Unlisted Market Valuation
Investors should continuously monitor these variables as they shape the premium or discount HLF commands relative to the theoretical merger-based price.
Read More : MSEI’s ₹1,240 Crore Fundraise
For investors looking to benefit from the evolving merger and valuation trends, understanding the interplay between HLF’s unlisted price and NDL Ventures’ listed price is crucial. This approach helps in making informed decisions backed by solid valuation math and market insights.
Ready to Invest or Seek Guidance on Unlisted Shares?
Explore detailed research, actionable insights, and hand-picked opportunities at Rits Capital. Connect with our expert advisors for personalized investment strategies tailored to unlisted equities and beyond.
Visit: RitsCapital
Call: 99110 90800
